[go: up one dir, main page]

MX2019001701A - FIXED DOSE PHARMACEUTICAL COMPOSITION INCLUDING MOMETASONE AND AZELASTINE. - Google Patents

FIXED DOSE PHARMACEUTICAL COMPOSITION INCLUDING MOMETASONE AND AZELASTINE.

Info

Publication number
MX2019001701A
MX2019001701A MX2019001701A MX2019001701A MX2019001701A MX 2019001701 A MX2019001701 A MX 2019001701A MX 2019001701 A MX2019001701 A MX 2019001701A MX 2019001701 A MX2019001701 A MX 2019001701A MX 2019001701 A MX2019001701 A MX 2019001701A
Authority
MX
Mexico
Prior art keywords
azelastine
pharmaceutical composition
fixed dose
dose pharmaceutical
composition including
Prior art date
Application number
MX2019001701A
Other languages
Spanish (es)
Other versions
MX390789B (en
Inventor
Agarwal Piyush
Chaudhari Sunil
Rajurkar Suresh
R Dhuppad Ulhas
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102013000830A external-priority patent/BR102013000830A2/en
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of MX2019001701A publication Critical patent/MX2019001701A/en
Publication of MX390789B publication Critical patent/MX390789B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica de dosis fija que comprende mometasona y azelastina. De forma particular, la presente invención proporciona una composición farmacéutica estable de dosis fija en la forma de un spray nasal que comprende mometasona o su sal y azelastina o su sal; y un proceso para preparar dicha composición, y su uso en el tratamiento de rinitis en un sujeto.The present invention relates to a fixed dose pharmaceutical composition comprising mometasone and azelastine. In particular, the present invention provides a stable fixed dose pharmaceutical composition in the form of a nasal spray comprising mometasone or its salt and azelastine or its salt; and a process for preparing said composition, and its use in treating rhinitis in a subject.

MX2019001701A 2012-12-06 2013-12-04 FIXED-DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND AZELASTINE. MX390789B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3454MU2012 2012-12-06
BR102013000830A BR102013000830A2 (en) 2013-01-11 2013-01-11 PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION, AND, USE OF THE SAME
PCT/IB2013/060638 WO2014087347A1 (en) 2012-12-06 2013-12-04 Fixed dose pharmaceutical composition comprising mometasone and azelastine

Publications (2)

Publication Number Publication Date
MX2019001701A true MX2019001701A (en) 2019-08-14
MX390789B MX390789B (en) 2025-03-21

Family

ID=50882873

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003546A MX2014003546A (en) 2012-12-06 2013-12-04 Fixed dose pharmaceutical composition comprising mometasone and azelastine.
MX2019001701A MX390789B (en) 2012-12-06 2013-12-04 FIXED-DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND AZELASTINE.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014003546A MX2014003546A (en) 2012-12-06 2013-12-04 Fixed dose pharmaceutical composition comprising mometasone and azelastine.

Country Status (7)

Country Link
EP (1) EP2928302A1 (en)
EA (1) EA037259B1 (en)
MX (2) MX2014003546A (en)
MY (1) MY196902A (en)
PH (1) PH12015501179A1 (en)
WO (1) WO2014087347A1 (en)
ZA (1) ZA201503799B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109288790A (en) * 2017-07-25 2019-02-01 健乔信元医药生技股份有限公司 Nasal pharmaceutical composition and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof

Also Published As

Publication number Publication date
MY196902A (en) 2023-05-09
WO2014087347A1 (en) 2014-06-12
EP2928302A1 (en) 2015-10-14
ZA201503799B (en) 2016-02-24
EA037259B1 (en) 2021-03-01
MX390789B (en) 2025-03-21
EA201491769A1 (en) 2015-06-30
MX2014003546A (en) 2014-12-09
PH12015501179A1 (en) 2015-08-17

Similar Documents

Publication Publication Date Title
CL2013001947A1 (en) Pharmaceutical composition comprising pioglitazone; use of pioglitazone to treat Alzheimer's; composition comprising pioglitazone.
CL2015002733A1 (en) Pharmaceutical composition of s-ketamine hydrochloride.
CR20150326A (en) AUTOTAXIN INHIBITORS
MX377410B (en) INTEGRIN RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE.
ECSP15007335A (en) SULFAMOILARYLAMIDES AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
CR20150629A (en) CHEMICAL COMPOUNDS
CL2015002164A1 (en) Combined formulation of two antiviral compounds.
ECSP15048122A (en) SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
MX365939B (en) Nuclear transport modulators and uses thereof.
MX365835B (en) Use of akkermansia for treating metabolic disorders.
CL2015000295A1 (en) Compounds derived from alkylpyrimidine; pharmaceutical composition that includes them; Use for the treatment of viral infections and other diseases.
AR092177A1 (en) METHODS TO TREAT OR PREVENT ASTHMA BY MANAGING AN IL-4R ANTAGONIST
CR20150114A (en) COVERED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
UA116999C2 (en) SELECTED HEMAGLUTIN ANTIBODY AND PHARMACEUTICAL COMPOSITION TO BE CONTAINED
CL2014001047A1 (en) Heterocyclic compounds derived from pyrazine; composition and pharmaceutical combination that contain them and the use in respiratory and allergic diseases.
NI201500096A (en) CHEMICAL COMPOUNDS
UY34775A (en) USE OF LAQUINIMOD IN HIGH DOSE FOR THE TREATMENT OF MULTIPLE SCLEROSIS
ECSP16008797A (en) DERIVATIVES OF HETEROBICICLOARIL AS RORC2 INHIBITORS AND METHODS OF USE OF THE SAME
CL2015000039A1 (en) Estra-1,3,5 (10), 16-tetraeno-3-substituted derivatives, pharmaceutical preparations that comprise them and their use in the preparation of medicaments for treating endometriosis.
CL2016000019A1 (en) Compounds derived from deuterated dihydroxyphenyl or a salt thereof; pharmaceutical composition that comprises them and their use for the treatment of neurotransmitter-mediated disorders such as hypotension, sleep disorders, Alzheimer's disease and depression.
UY36292A (en) TETRAHYDROQUINOLINE COMPOUNDS FOR USE AS BROMODOMINIUM INHIBITORS
CL2014002845A1 (en) Compounds derived from pyrazole sglt1 inhibitors; method to treat diabetes; pharmaceutical composition; use of the compound for the treatment of type 1 and type 2 diabetes.
BR112014009760A2 (en) sialic acid analogs, their use and pharmaceutical composition and sustained release pharmaceutical composition comprising them
CL2015001502A1 (en) Pharmaceutical composition comprising desloratadine and prendnisolone and use thereof.
MX2019001701A (en) FIXED DOSE PHARMACEUTICAL COMPOSITION INCLUDING MOMETASONE AND AZELASTINE.